News & Events

< Back to News Overview

GBS continues its winning streak of exits

28 / 09 / 2018

At the 2018 AVCAL Annual Awards held in September on Queensland's Gold Coast, GBS portfolio company Elastagen Pty Ltd was recognized as the best Venture Capital Investment.
Elastagen, sold to Allergan for up to USD $260m US earlier this year, joins previous GBS winners Spinifex (Best Venture Capital Investment 2015) sold for up to USD $700m, Hatchtech (Best Venture Capital Investment 2016) sold for up to AUD $300m, and Neurovance sold for up to USD $1,000m in 2017.

"It's great to see Australian life sciences continuing to deliver institutional investors strong exits, and strong financial returns.  As these deals deliver milestone payments in the years to come, we will deliver our investors even better returns." said Brigitte Smith, GBS Managing Director.

Brigitte Smith was awarded a 25th Anniversary Award for Outstanding Contribution to the Industry.

"All of the award winners are leaders who have demonstrated exceptional investment execution strategy through the work they have done to grow and expand good businesses, transforming them into great businesses," said Mr El-Ansary.